{"schema_version":"secwatch.filing_event.v1","accession":"0001698530-23-000006","form_type":"8-K","ticker":"XCUR","cik":"0001698530","company_name":"EXICURE, INC.","filed_at":"2023-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.184664+00:00","generated_at":"2026-06-20T12:34:38.581530+00:00","sec_items":["3.01","5.02","7.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Exicure receives Nasdaq delisting notice for board independence; director resigns","bullets":["Jan 19, 2023: Nasdaq notifies Exicure of non-compliance with Listing Rule 5605 (independent director/audit committee requirements). Cure period ends at earlier of 2023 annual meeting or Dec 30, 2023.","Director Jiyoung Hwang resigned effective Jan 16, 2023; no disagreement with company operations, policies, or practices.","Company actively seeking qualified independent director to regain compliance; must comply by June 28, 2023 if annual meeting before that date.","Private placement of 3,400,000 shares at $1.60/share with CBI USA expected to close by Feb 10, 2023 (previously disclosed Sep 26, 2022)."],"urls":{"canonical":"https://secwatch.observer/filing/0001698530-23-000006","json":"https://secwatch.observer/filing/0001698530-23-000006.json","markdown":"https://secwatch.observer/filing/0001698530-23-000006.md","text":"https://secwatch.observer/filing/0001698530-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1698530/000169853023000006/0001698530-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1698530/000169853023000006/xcur-20230116.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T12:34:38.581530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70e282a6d87f96e18f878c437431da9a15ca14ab","claim":"EXICURE, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(b)(1)(A), 5605(c)(4)).","evidence_excerpt":"January 19, 2023, Exicure, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is no longer in compliance with Nasdaq’s independent director and audit committee requirements as set forth in Nasdaq Listing Rule 5605, which requires the board of directors to be comprised of a majority of independent directors and the audit committee of the board of directors to be comprised of three independent directors (the “Listing Requirement”). Pursuant to Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4), the Company is entitled to a cure period to regain compl","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1698530/000169853023000006/0001698530-23-000006-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"audit committee"},{"label":"Rules","value":"5605, 5605(b)(1)(A), 5605(c)(4)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"9e2d9bf441","claim":"Jiyoung Hwang resigned as Director at EXICURE, INC..","evidence_excerpt":"On January 16, 2023, Jiyoung Hwang tendered her resignation from the Board, effective immediately as of such date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1698530/000169853023000006/0001698530-23-000006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}